Deep-vein thrombosis in Europe — Burden of illness in relationship to healthcare resource utilization and return to work

Chuang, Ling-Hsiang; Hout, Ben van; Cohen, Aloni; Gumbs, Pearl D.; Kroep, Sonja; Bauersachs, Rupert; Gitt, Anselm K.; Monreal, Manuel; Willich, Stefan N.; Agnelli, Giancarlo

doi:10.1016/j.thromres.2018.08.001

Cited by 14 publications

(16 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Detailed baseline characteristics per country are reported elsewhere. 7 Patients with active cancer were significantly older and had a higher proportion of liver disease and history of major surgery or trauma. Patients with active cancer had fewer previous VTE events and reported less alcohol use, cardiovascular disease, prolonged immobilization, and varicose veins.…”

Section: Resultsmentioning

confidence: 99%

“…Direct oral anticoagulants were infrequently used in Italy and Spain at the time of the data collection. 7 Health-Related Quality of Life At baseline, 1921 patients completed the HrQoL questionnaire, 1366 at 1 month, 1163 at 3 months, 1013 at 6 months, and 847 patients completed the HrQoL questionnaire at 12 months. Figure 1 presents the distribution of each dimension of EQ-5D-5L and death at baseline and each follow-up for patients with active cancer and those without.…”

Section: Patients Characteristicsmentioning

confidence: 99%

See 1 more Smart Citation

Deep Vein Thrombosis in Europe—Health-Related Quality of Life and Mortality

Monreal

Agnelli

Chuang

et al. 2019

Clin Appl Thromb Hemost

Self Cite

View full text Add to dashboard Cite

Objectives: Deep vein thrombosis (DVT) is a major health-care burden in Europe, but exact estimates are lacking. This study reports results from the PREFER venous thromboembolism (VTE) study concerning health-related quality of life (HrQoL) and mortality of patients with DVT. Methods: PREFER VTE was a prospective, observational study, conducted in 7 European countries, designed to provide data concerning treatment patterns, resource utilization, mortality, and QoL. First-time or recurrent patients with DVT were followed at 1, 3, 6, and 12 months. Health-related QoL—as measured by the EuroQoL 5-Dimension 5-Level instrument ( EQ-5D-5L)—was analyzed using Tobit regression with repeated measures, assessing the impact of baseline characteristics stratified by cancer activity. Mortality was analyzed using logistic regression. Results: At baseline, patients with DVT had a 0.14 lower EQ-5D-5L index score (0.72 for total sample) compared to the reference UK population (0.85). The EQ-5D-5L index score improved from baseline to 12 months in patients with active cancer (from 0.70 to 0.79) and those without (0.72-0.87); 7.3% died within a year, a 5.2% excess mortality compared to the age- and gender-adfjusted general population. The 12-month mortality rate of DVT varied between 2.9% in the pooled data from Germany, Switzerland, or Austria and 15.4% in Italy. Furthermore, the mortality rate differed between patients with active cancer and those without (42.9% vs 4.7%). Conclusions: Deep vein thrombosis is associated with a substantial burden of illness in terms of HrQoL at baseline, which following treatment normalizes after 12 months and has a significant mortality rate. In addition, active cancer has a significant impact on mortality and the HrQoL of patients with DVT.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Patients Characteristicsmentioning

confidence: 99%

Deep Vein Thrombosis in Europe—Health-Related Quality of Life and Mortality

Monreal

Agnelli

Chuang

et al. 2019

Clin Appl Thromb Hemost

Self Cite

View full text Add to dashboard Cite

show abstract

“…anticoagulants, COVID-19, pulmonary embolism, severe acute respiratory syndrome coronavirus 2, thrombosis, venous thrombosis excess health care costs. [26][27][28][29][30][31][32][33][34][35] However, the long-term outcomes of COVID-19-associated VTE are currently unknown.…”

Section: Introductionmentioning

confidence: 99%

“…In the general (non‐COVID) population, the post‐PE syndrome and postthrombotic syndrome (PTS) have been reported to occur in 50% of people with VTE despite adequate anticoagulation therapy 26,27 . These long‐term complications have a major impact on quality of life and are associated with higher risks of depression, unemployment, social isolation, and excess health care costs 26‐35 . However, the long‐term outcomes of COVID‐19–associated VTE are currently unknown.…”

Section: Introductionmentioning

confidence: 99%

Caging the dragon: Research approach to COVID‐19–related thrombosis

Kruip

Cannegieter

Cate

et al. 2021

Research and Practice in Thrombosis and Haemostasis

View full text Add to dashboard Cite

The incidence of venous thrombosis, mostly pulmonary embolism (PE), ranging from local immunothrombosis to central emboli, but also deep vein thrombosis (DVT) in people with coronavirus disease 2019 (COVID‐19) is reported to be remarkably high. The relevance of better understanding, predicting, treating, and preventing COVID‐19–associated venous thrombosis meets broad support, as can be concluded from the high number of research, review, and guideline papers that have been published on this topic. The Dutch COVID & Thrombosis Coalition (DCTC) is a multidisciplinary team involving a large number of Dutch experts in the broad area of venous thrombosis and hemostasis research, combined with experts on virology, critically ill patients, pulmonary diseases, and community medicine, across all university hospitals and many community hospitals in the Netherlands. Within the consortium, clinical data of at least 5000 admitted COVID‐19–infected individuals are available, including substantial collections of biobanked materials in an estimated 3000 people. In addition to considerable experience in preclinical and clinical thrombosis research, the consortium embeds virology‐hemostasis research models within unique biosafety facilities to address fundamental questions on the interaction of virus with epithelial and vascular cells, in relation to the coagulation and inflammatory system. The DCTC has initiated a comprehensive research program to answer many of the current questions on the pathophysiology and best anticoagulant treatment of COVID‐19–associated thrombotic complications. The research program was funded by grants of the Netherlands Thrombosis Foundation and the Netherlands Organization for Health Research and Development. Here, we summarize the design and main aims of the research program.

show abstract

“…Despite universal usage of anticoagulants, post-thrombotic syndrome (PTS) is the most frequent long-term complication of lower limb DVT, affecting about 23% to 60% of patients within 2 years even with an adequate treatment, major symptoms being chronic pain and edema of the lower limb [1,2]. PTS is severe in 5-10% of cases degrading the quality of life and inducing an economic burden [3,4]. Proximal thrombosis, involving iliac veins, is more at risk of PTS.…”

Section: Introductionmentioning

confidence: 99%

Single-Session Percutaneous Mechanical Thrombectomy Using the Aspirex®S Device Plus Stenting for Acute Iliofemoral Deep Vein Thrombosis: Safety, Efficacy, and Mid-Term Outcomes

Loffroy¹,

Falvo²,

Guillen³

et al. 2020

Diagnostics

View full text Add to dashboard Cite

To assess the safety, efficacy and mid-term outcomes of single-session percutaneous mechanical thrombectomy (PMT) for acute symptomatic iliofemoral deep vein thrombosis (DVT) using the Aspirex®S device. Retrospective review of 30 patients (women, 23; mean age, 45.5 ± 19.9 years; range, 17–76) who underwent PMT with the 10-French Aspirex®S device (Straub Medical AG, Wangs, Switzerland) for acute DVT between December 2015 and March 2019. Procedures were performed by popliteal (n = 22) or jugular (n = 7) approach, or both (n = 1). Mean time from diagnosis to PMT was 5.5 ± 4.6 days (range, 2–11). Successful thrombus removal and venous patency restoration were achieved in all patients (100%). Fluid removal was 307.8 ± 66.1 mL (range, 190–410). Additional venous stenting rate was 100%. Mean procedural time was 107.3 ± 33.9 min (range, 70–180). No major complication occurred. The patient’s postprocedural course was uneventful in all cases, with hospital discharge within 2 days in 83.3%. Early in-stent rethrombosis occurred within 1 week in 3 patients, successfully managed by endovascular approach. Secondary stent patency rate was 86.7% at a mean follow-up of 22.3 ± 14.2 months (range, 6–48), as assessed by Duplex ultrasound. Single-session of PMT using the Aspirex®S device is a safe and effective therapeutic option in patients presenting with acute symptomatic iliofemoral DVT.

show abstract

Deep-vein thrombosis in Europe — Burden of illness in relationship to healthcare resource utilization and return to work

Abstract: Medical treatment of DVT differed between patients with active cancer and those without. Post-VTE or VTE-related resource utilization differs remarkably between countries. Work-loss seems high, but questions may be raised concerning the causality due to the presence of co-morbidities.

Cited by 14 publications

References 16 publications

Deep Vein Thrombosis in Europe—Health-Related Quality of Life and Mortality

Deep Vein Thrombosis in Europe—Health-Related Quality of Life and Mortality

Caging the dragon: Research approach to COVID‐19–related thrombosis

Single-Session Percutaneous Mechanical Thrombectomy Using the Aspirex®S Device Plus Stenting for Acute Iliofemoral Deep Vein Thrombosis: Safety, Efficacy, and Mid-Term Outcomes

Contact Info

Product

Resources

About